MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
CorMedix Long Term Debt Current 2011-2025 | CRMD
Annual Long Term Debt Current CorMedix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151 K | 135 K | 121 K | 109 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 151 K | 109 K | 129 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.9 | 4.03 % | $ 813 M |  Canada |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
481 K | $ 3.21 | -1.38 % | $ 248 M |  USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
800 K | $ 1.06 | -6.22 % | $ 293 K | USA |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 13.33 | -5.39 % | $ 878 M | USA |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 214.55 | -2.66 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.1 | -5.93 % | $ 7.46 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
1.45 M | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
829 K | $ 88.51 | 0.59 % | $ 9.14 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
402 K | $ 24.35 | 3.07 % | $ 2.88 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | $ 5.02 | -0.59 % | $ 934 M | Germany |
 |
BioVie
BIVI
|
74.5 K | $ 1.43 | -1.72 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
BioNTech SE
BNTX
|
39.5 M | $ 93.99 | -0.86 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.18 M | $ 10.88 | 0.74 % | $ 1.41 B | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 26.44 | 4.63 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
1.6 M | $ 9.6 | 0.42 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
5.38 M | $ 15.97 | -4.37 % | $ 410 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 0.26 | -6.9 % | $ 566 M |  Israel |
 |
Evogene Ltd.
EVGN
|
589 K | $ 1.04 | -3.7 % | $ 27.9 M | Israel |
 |
Exelixis
EXEL
|
25 M | $ 41.27 | 0.95 % | $ 12 B | USA |
 |
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
|
Foghorn Therapeutics
FHTX
|
9.07 M | $ 4.39 | -1.13 % | $ 241 M | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
9.45 M | $ 551.37 | -2.29 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.35 | 2.17 % | $ 14.8 M | USA |
 |
AstraZeneca PLC
AZN
|
339 M | $ 91.19 | 1.51 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.25 | -2.43 % | $ 728 M | USA |
 |
Biogen
BIIB
|
86.4 M | $ 174.69 | 0.34 % | $ 25.4 B | USA |